Literature DB >> 15041107

An extended 10-core transrectal ultrasonography guided prostate biopsy protocol improves the detection of prostate cancer.

Saadettin Yilmaz Eskicorapci1, Dilek Ertoy Baydar, Cem Akbal, Mustafa Sofikerim, Mert Günay, Sinan Ekici, Haluk Ozen.   

Abstract

OBJECTIVE: To evaluate the efficacy of TRUS guided 10-core biopsy strategy for Turkish patients who had biopsy of the prostate for the first time.
METHODS: Between February 2001 and May 2003, 303 consecutive men with suspected prostate cancer were included in the study. Indications for TRUS guided prostate biopsy were: abnormal digital rectal examination and/or a serum PSA over 2.5 ng/ml. All of the patients underwent a 10-core biopsy protocol with additional core from the each suspicious area detected by TRUS. Besides the sextant technique, 4 more biopsies were obtained from the lateral peripheral zone. We aimed to analyze whether cancer detection improved with the extended versus the standard sextant biopsy in our series overall and in each subgroup.
RESULTS: Of 303 patients 94 (31%) were positive for prostate cancer. Median age and PSA of prostate cancer patients were significantly higher than of the non-cancer patients. Besides prostate volumes of the cancer patients were significantly lower than of the non-cancer ones. The cancer detection rates were 31% (94/303) and 23.1% (70/303) for the 10-core biopsy strategy and sextant biopsy strategies, respectively. Thus the 10-core biopsy technique increased cancer detection rate by 25.5% (24/94) for the whole group of patients. A statistically significant number of additional cancers were detected with 10-core biopsy strategy for all the subgroups of the patients. Furthermore 10-core biopsy protocol detected more cancers (at least 6.4%) than all the probable different combinations of 8-core biopsy protocols. Among the 94 cancer patients, biopsy from a suspicious area revealed cancer in 31.9% of them; however, in all of these patients cancer was already present in the 10-core biopsy. On the other hand, lesion biopsies revealed 5.7% additional cancers if sextant technique was used. There were only 3 (0.9%) serious complications requiring hospitalization and all 3 were infections controlled by appropriate antibiotics.
CONCLUSION: Adding 4 lateral peripheral biopsies to the conventional sextant biopsy (10-core biopsy strategy) technique has increased the cancer detection rate by 25.5% without significant morbidity and without increasing the number of insignificant cancers. 10-core biopsy protocol was superior to all probable 8-core biopsy protocols in our study group. Additional biopsies from suspicious areas detected by transrectal ultrasonography revealed no further benefit if 10-core technique was used. We therefore suggest that 10-core biopsy protocol should be the preferred strategy in early detection of prostate cancer.

Entities:  

Mesh:

Year:  2004        PMID: 15041107     DOI: 10.1016/j.eururo.2003.11.024

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  31 in total

Review 1.  When prostate cancer remains undetectable: The dilemma.

Authors:  Mahmoud Othman Mustafa; Louis Pisters
Journal:  Turk J Urol       Date:  2015-03

Review 2.  A comparison of the diagnostic performance of systematic versus ultrasound-guided biopsies of prostate cancer.

Authors:  Stijn W T P J Heijmink; Hilco van Moerkerk; Lambertus A L M Kiemeney; J Alfred Witjes; Ferdinand Frauscher; Jelle O Barentsz
Journal:  Eur Radiol       Date:  2006-01-04       Impact factor: 5.315

3.  Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.

Authors:  Andrew J Vickers; Angel M Cronin; Gunnar Aus; Carl-Gustav Pihl; Charlotte Becker; Kim Pettersson; Peter T Scardino; Jonas Hugosson; Hans Lilja
Journal:  Cancer       Date:  2010-06-01       Impact factor: 6.860

4.  Follow-up of men obtaining a six-core versus a ten-core benign prostate biopsy 7 years previously.

Authors:  Clemens Brossner; Stefan Madersbacher; Phillip de Mare; Anton Ponholzer; Bader Al-Ali; Michael Rauchenwald
Journal:  World J Urol       Date:  2005-12-03       Impact factor: 4.226

5.  Minimum 6 mm core length is strongly predictive for the presence of glandular tissue in transrectal prostate biopsy.

Authors:  Hasan Yilmaz; Seyfettin Ciftci; Murat Ustuner; Ufuk Yavuz; Ali Saribacak; Bahar Muezzinoglu; Ozdal Dillioglugil
Journal:  World J Urol       Date:  2015-03-17       Impact factor: 4.226

6.  Automated prostate cancer detection using T2-weighted and high-b-value diffusion-weighted magnetic resonance imaging.

Authors:  Jin Tae Kwak; Sheng Xu; Bradford J Wood; Baris Turkbey; Peter L Choyke; Peter A Pinto; Shijun Wang; Ronald M Summers
Journal:  Med Phys       Date:  2015-05       Impact factor: 4.071

7.  The detection of significant prostate cancer is correlated with the Prostate Imaging Reporting and Data System (PI-RADS) in MRI/transrectal ultrasound fusion biopsy.

Authors:  Hannes Cash; Andreas Maxeiner; Carsten Stephan; Thomas Fischer; Tahir Durmus; Josephine Holzmann; Patrick Asbach; Matthias Haas; Stefan Hinz; Jörg Neymeyer; Kurt Miller; Karsten Günzel; Carsten Kempkensteffen
Journal:  World J Urol       Date:  2015-08-21       Impact factor: 4.226

8.  Comparison of 8, 10, 12, 16, 20 cores prostate biopsies in the determination of prostate cancer and the importance of prostate volume.

Authors:  Cavit Ceylan; Omer Gokhan Doluoglu; Erdogan Aglamis; Ozkan Baytok
Journal:  Can Urol Assoc J       Date:  2014 Jan-Feb       Impact factor: 1.862

9.  [The Prostate Cancer Prevention Trial (PCPT). Relevance for clinical practice].

Authors:  B J Schmitz-Dräger; C Fischer; E Bismarck; H J Dörsam; G Lümmen
Journal:  Urologe A       Date:  2007-10       Impact factor: 0.639

10.  The importance of prostate volume in prostate needle biopsy.

Authors:  Ömer Gökhan Doluoğlu; Çetin Volkan Öztekin; Mehmet Karabakan; Alp Özgür Akdemir; Mesut Çetinkaya
Journal:  Turk J Urol       Date:  2013-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.